Morgan Stanley analyst James Quigley downgraded Bayer to Equal Weight from Overweight with a price target of EUR 62, down from EUR 80. Bayer continues to look attractive on valuation terms, but Quigley sees limited upside catalysts, thinks Crop growth will be held back by glyphosate pricing headwinds and calls 2023 an investment year in Pharma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAYRY: